NASA’s Moon Base Plan Is Really a Bet on Lunar Logistics - Spacetech Industry Examiner By pausing Gateway in its current form and redirecting Artemis toward the lunar south pole, NASA is not just changing mission architecture. It is betting that

NASA’s moon base plan is really a bet on lunar logistics.

Not just landings — but cargo, power, cadence, mobility, and the supply chain needed to sustain operations at the lunar south pole.

That may be the real moonshot.

#SpaceTech #NASA #Artemis #MoonBase #LunarEconomy #TechNews

Money is becoming software — but the real question is whose money, on what rails, and under what rules.

Our latest feature explores why #BMO, CME Group, and #Google Cloud may be pointing toward one of fintech’s biggest next shifts: tokenized bank money built for a 24/7 financial system.

#Fintech

AI’s Next Bottleneck Is Electricity — and Climate Tech May Be the Real Winner - ClimateTech Industry Examiner Crusoe’s latest battery deals are not really about batteries. They are about what happens when AI collides with the grid — and why the next winners in climate

AI’s next bottleneck may not be chips.

It may be electricity.

Our latest feature argues the AI race is becoming an infrastructure race — and that batteries, grid flexibility, substations, and power delivery could matter more than many expected.

#ClimateTech #AI #DataCenters #Grid #TechNews

Merck’s $6.7B Terns buy is less about leukemia than life after Keytruda.

When one drug drives nearly half of revenue, M&A becomes a way to buy time before the patent cliff.

#Biotech #Pharma #Merck #Oncology #PatentCliff #BiotechM&A #TechNews #BioTechNews

The old ranch was built with wire. The next one may be drawn on a smartphone.

Halter’s $220M raise is a fascinating test of whether virtual fencing is becoming real infrastructure, not just an agtech demo.

#AgTech #VirtualFencing #LivestockTech #Ranching #TechNews #IndustryExaminer

Biotech’s AI Race Is No Longer About Models. It’s About Infrastructure. - Biotech Industry Examiner Roche’s latest Nvidia build is not just another AI headline. It is a sign that in biotech, the next real advantage may come from owning the compute, data and

Biotech AI is becoming an infrastructure race.

Roche’s latest Nvidia build points to a bigger shift: the next pharma moat may come from compute, data and workflows at scale.

biotech.industryexaminer.com/biotech-ai-i...

#Biotech #AI #Pharma #Roche #NVIDIA #TechNews #IndustryExaminer

Anduril’s ExoAnalytic deal is about more than telescopes. It’s a bet that the next edge in missile defense will come from owning the orbital picture: tracking, data, software, and command.

#SpaceTech #DefenseTech #GoldenDome #MissileDefense #TechNews #DeepSpace

London’s fintech rise is not just a ranking story. It reflects a deeper shift in what the market rewards: regulation, infrastructure, institutional depth, and resilience over hype.

Our latest feature:

#Fintech #London #UKFintech #VC #Payments #DigitalBanking #FintechNews #TechNews

The Next Solar Race Is Not About Cost. It’s About Reliability. - ClimateTech Industry Examiner Masdar’s giant Abu Dhabi project is designed to do something solar has rarely been asked to do at utility scale: deliver a steady block of electricity around

Solar won the cost argument years ago. The harder test is reliability.
Masdar’s Abu Dhabi project pairs 5.2 GW of solar with 19 GWh of storage to target 1 GW of round-the-clock power. That could reshape how clean power is sold.

#ClimateTech #Solar #EnergyStorage #TechNews #SolarNews #Masdar

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation - Biotech Industry Examiner The rovadicitinib deal is about more than one blood-cancer and transplant asset. It is another sign that global pharma is no longer treating China mainly as a

China is no longer just a biotech market. It is increasingly a source of licensable innovation for global pharma.

Sanofi’s up-to-$1.53B rovadicitinib deal is the latest signal — and part of a much bigger shift in where drug innovation begins.

#Biotech #Pharma #ChinaBiotech #BiotechNews #TechNews

Biologicals want to go mainstream.
They may first have to earn it on the seed.
Our latest #AgTech feature looks at why seed treatment could become the real proving ground for crop biologicals — with Ascribe Bio, Corteva, and the wider competitive context around Syngenta and BASF.
#Biologicals

Sierra Space’s $550M raise at an $8B valuation is more than a funding headline. It shows what private space is being rewarded for now: defense relevance, factory capacity, and execution.
spacetech.industryexaminer.com/sierra-space...

#SpaceTech #DefenseTech #Aerospace #TechNews #SpaceNews

Revolut’s U.S. bank-charter bid isn’t just an expansion play—it’s a bet on governance.

A charter means deposits + lending control, but also bank-grade scrutiny: BSA/AML, resilience, consumer compliance, board oversight.
#FinTech #DigitalBanking #Regulation #TechNews #BankingNews #RegTech

Europe’s Industrial Accelerator Act: “Buy EU,” but Make It Low-Carbon - ClimateTech Industry Examiner On March 4, the European Commission unveiled the Industrial Accelerator Act (IAA)—a legislative proposal that reads like a memo from an anxious boardroom:

Europe is turning climate targets into procurement rules. The proposed Industrial Accelerator Act aims to lift manufacturing from 14.3% of EU GDP (2024) to 20% by 2035 — with “lead markets” for low-carbon steel/cement/aluminium + local-content EV rules.
#ClimateTech #EU #IndustrialPolicy #TechNews

The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing - Biotech Industry Examiner On March 2, 2026, the U.S. Food and Drug Administration removed the clinical hold on Intellia Therapeutics’ MAGNITUDE Phase 3 trial—restarting a program that

FDA lifted the clinical hold on Intellia’s MAGNITUDE Phase 3 (ATTR-CM). The headline says “resume.”

The real story: a safety reset—tighter selection + heavier liver monitoring + explicit mitigation steps.

biotech.industryexaminer.com/crispr-safet...

#CRISPR #Biotech #ClinicalTrials #TechNews

Waste to Yield: The Vietnam Rice Trial Claiming a 43% Jump—and the Questions That Matter - Agtech Industry Examiner A 43% yield increase is the kind of number that makes agronomists squint. That’s exactly what a recent field demonstration […]

Vietnam rice trial: waste-derived biostimulant, +43% yield (688.7 vs 482.8 kg/0.1 ha). Big upside—but ask: replications? fertilizer rates? multi-season proof? Read: agtech.industryexaminer.com/waste-to-yie...
#AgTech #Biostimulants #Rice #Vietnam #SustainableAgriculture #TechNews

Space Force gave Mission Delta 9 a live satellite (launched on USSF-87, Feb 12) to practice “precise, advanced” GEO maneuvers. In space, movement = fuel + lifespan + signaling (and escalation risk). spacetech.industryexaminer.com/space-force-...
#SpaceForce #SpaceTech #GEO

Stripe: $1.9T. PayPal: $1.79T + 439M accounts. If Stripe buys PayPal (or parts), the prize isn’t volume—it’s checkout identity: who gets to say “yes.” Read: fintech.industryexaminer.com/stripe-paypa...
#Fintech #Payments #PayTech #MergersAndAcquisitions #Stripe #PayPal #TechNews

To Scale Direct Air Capture, Build Power First: The Solar-Backed STRATOS Bet in West Texas - ClimateTech Industry Examiner When a company announces a 500-megawatt solar complex to support an oil major’s operations in West Texas, you expect the usual suspects: electrified field

DAC doesn’t scale on chemistry. It scales on power.

West Texas: 500 MW solar ↔ STRATOS (500k t/yr). The question: can carbon removal scale without cannibalizing clean electricity?

climatetech.industryexaminer.com/solar-powere...

#ClimateTech #CarbonRemoval #DirectAirCapture #DAC #Grid #CCUS

Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T - Biotech Industry Examiner On February 23, 2026, Gilead agreed to acquire Arcellx in a deal valued at up to $7.8 billion—a headline number that’s easy to file under “Big Pharma goes

Gilead’s $7.8B Arcellx buy isn’t just M&A. It’s an “option exercise” on CAR-T: pay up to own the flywheel—manufacturing, label expansion, and the economics of scale.

biotech.industryexaminer.com/gilead-arcel...

#Biotech #CellTherapy #CART #Oncology #M&A #TechNews #BiotechNews #MultipleMyeloma

Kubota’s €6.5m wager on a single drop: why vegetable weeding is becoming a software problem - Agtech Industry Examiner On Feb. 18, 2026, Norwegian agtech startup Kilter disclosed a €6.5 million strategic investment from Kubota as it gears up […]

€6.5m in. Kilter says its AX-1 targets weeds at ~6mm and can cut herbicide use “up to 95%” by treating only where weeds exist. Kubota just made a strategic bet on that shift: selectivity moves from chemistry → software. agtech.industryexaminer.com/kubota-kilte... #AgTech #FarmRobotics #TechNews

Artemis II's Feb 19 wet dress rehearsal hit T-29s after a recycle, with hydrogen levels under limits. Next: data review + launch date call (earliest Mar 6). spacetech.industryexaminer.com/nasa-artemis... #ArtemisII #NASA #SLS #Orion #SpaceTech #LaunchOperations #Moon #TechNews #SpaceNews

Adani’s $100B “energy + compute” bet is a ClimateTech story — not just an AI story - ClimateTech Industry Examiner Adani says the roadmap will expand AdaniConneX’s existing 2 GW national data-centre platform toward a 5 GW target.

5 GW of data centers is an energy-system problem, not an IT project. Adani's plan (2 GW -> 5 GW) raises the real question: can renewables + storage deliver 24/7 power for AI? climatetech.industryexaminer.com/adani-100b-r...
#ClimateTech #AI #DataCenters #EnergyStorage #Grid #India #Adani #TechNews

Abu Dhabi Wants to Own Longevity Biotech—and Juvenescence Is the Test Case - Biotech Industry Examiner On Feb. 16, 2026 (PT), Juvenescence—a clinical-stage, AI-enabled longevity biotech—said it is establishing new research offices at Masdar City and hiring

Abu Dhabi wants to own longevity biotech. Juvenescence’s Masdar City AI lab is the test case: 800k+ genomes, 900k+ biobank samples—now prove it in trials. Full take: biotech.industryexaminer.com/abu-dhabi-lo...
#longevity #biotech #ai #genomics #abudhabi #uae #TechNews

The fertilizer robot trying to turn nitrogen into a “just-in-time” input - Agtech Industry Examiner Upside Robotics says its small autonomous machines can cut corn nitrogen use by as much as 70% — and save […]

If fertiliser is ~45% of corn’s direct costs, timing is money. Upside Robotics says its rover can cut nitrogen use by up to 70% via micro-dosing. The catch: throughput, uptime, and yield risk. agtech.industryexaminer.com/fertilizer-r...
#AgTech #PrecisionAgriculture #FarmRobotics #UpsideRobotics

China logged 93 orbital launches in 2025—about one in three globally. The bigger story: megaconstellations + spectrum filings are turning LEO into scarce “real estate”. What happens when everyone shows up at once?
spacetech.industryexaminer.com/china-space-...
#SpaceTech #LEO #TechNews

Europe’s digital euro gets real: online + offline.

Cash is still 52% of POS but online is 21% of payments (36% by value). And ~2/3 of euro-area card transactions run via non-European firms

Why a ‘public option’ for payments is back: fintech.industryexaminer.com/europe-digit...
#DigitalEuro #CBDC

Can “salt batteries” solve the AI data-centre power crunch? - ClimateTech Industry Examiner A new partnership between Energy Vault and Peak Energy bets that sodium-ion storage can do two things at once: cut fire risk and cut time-to-power for AI

AI data centres don’t just need more power — they need it on time. A 1.5 GWh US-made sodium-ion deal (Energy Vault + Peak) targets behind-the-meter power buffering for AI loads. Chemistry won’t fix grid queues — but it can buy time.
climatetech.industryexaminer.com/sodium-ion-a...
#ClimateTech

Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug? - Biotech Industry Examiner On February 9, Eli Lilly agreed to buy Orna Therapeutics for up to $2.4bn in cash, betting that one of biotech’s most powerful treatment ideas — CAR-T cell

CAR-T works. But it’s bespoke: collect cells, engineer, ship back — often 3–6 weeks. Lilly’s up-to-$2.4bn Orna deal bets on in-vivo CAR-T (circular RNA + LNPs) to make an autoimmune “immune reset” scalable. biotech.industryexaminer.com/lilly-orna-i...
#Biotech #CART #EliLilly #TechNews #BiotechNews

Koppert + Certhon are building a 3,500 m² climate-controlled flour-moth facility near Rotterdam. The message: biocontrol is becoming manufacturing.
agtech.industryexaminer.com/koppert-cert...
#AgTech #Biocontrol #IPM #GreenhouseTech #SupplyChain #TechNews